All Articles

ChipMOS Technologies' May revenue surged 17.7% year-over-year, fueled by AI chip demand. Despite a minor monthly dip, the firm is expanding capacity.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

Questex's Fierce Biotech is launching a UK event, but this is more than expansion. It’s a calculated bet on London's future as a biotech superpower.

Logitech's new Mobi Fold isn't just a clever gadget. It's a strategic assault on the trackpad, aiming to close the productivity gap for hybrid professionals.

A strategic pivot from commercial real estate to the hard assets of the new economy reveals where the smart money is flowing—and it’s not just into buildings.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

Beyond art and music, China's UN-backed event in Geneva reveals a calculated investment in global influence, aiming to reshape multilateralism itself.

Leading Edge Materials confirms a low-cost, high-purity graphite process at its Swedish mine, positioning Woxna to supply Europe's booming EV battery market.

A new deal to push advanced solar tech into emerging markets is more than a sales win; it's a strategic blueprint for navigating the future of global energy.

A landmark deal locks in energy for Ukraine and Finland until 2044, cementing a small Baltic terminal as a powerhouse of European strategic resilience.

A new campaign pairs a star athlete with a robotic mower, revealing a deeper strategy to win the multi-billion-dollar race for autonomous home care.

A new study by SciBase and Castle Biosciences is testing technology to predict atopic dermatitis flares, promising a shift from reactive care to patient control.

Japanese artist Takuma Tanaka's journey from law to canvas culminates in a Miami exhibition that channels Bruce Lee's wisdom to challenge modern overthinking.

A global health giant is now targeting the world's financial system, arguing that crippling debt is a deadlier crisis than any disease. Is their plan a revolution or a fantasy?

In just two years, AIKO Energy has captured a significant slice of Australia's solar market. We dissect the strategy combining breakthrough tech and local focus.

Metrica Partners' public battle with WUS Printed Circuit exposes a billion-dollar valuation gap, testing Taiwan's new corporate governance reforms.

Biotech firm Sensorion drops one gene therapy to fast-track another, aiming to cure GJB2-related hearing loss, the leading cause of genetic deafness.

A new AI platform from Bell Integration and IBM aims to end IT 'firefighting.' We look under the hood at the tech and strategy driving this major shift.